Loading
Breast oncologist who led MONALEESA-2, the first CDK4/6 trial to show an overall survival gain in first-line HR-positive disease.
Gabriel Hortobagyi has run breast cancer trials at MD Anderson for four decades and was principal investigator of MONALEESA-2, which showed ribociclib plus letrozole improves progression-free and then overall survival in postmenopausal HR-positive advanced breast cancer. He has chaired ASCO and helped write the AJCC staging system for breast cancer. His work continues on endocrine resistance and adjuvant CDK4/6 inhibition.
Shares CDK4/6, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tags breast, trialist.
Shares MD Anderson Cancer Center and the tags breast, trialist.
Shares CDK4/6, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tags breast, trialist.
Shares Inflammatory breast cancer, CDK4/6, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tag breast.
Shares HR-positive / HER2-negative breast cancer and the tags breast, trialist.
Shares HR-positive / HER2-negative breast cancer and the tags breast, trialist.
Shares the tags breast, trialist.
Shares the tags breast, trialist.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/